Exact Mass: 473.3538606000001

Exact Mass Matches: 473.3538606000001

Found 34 metabolites which its exact mass value is equals to given mass value 473.3538606000001, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

23-Acetoxysoladulcidine

16-Hydroxy-5,7,9,13-tetramethyl-5-oxaspiro[pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,2-piperidine]-3-yl acetic acid

C29H47NO4 (473.3504902)


(23R)-Acetoxytomatidine is an alkaloid from roots of a Lycopersicon esculentum/Lycopersicon hirsutum hybri

   

Docosa-4,7,10,13,16-pentaenoyl carnitine

3-[(4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoyloxy]-4-(trimethylazaniumyl)butanoate

C29H47NO4 (473.3504902)


Docosa-4,7,10,13,16-pentaenoyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] Docosa-4,7,10,13,16-pentaenoyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).

   

Clupanodonyl carnitine

3-[(4E,8E,12E,15E,19E)-docosa-4,8,12,15,19-pentaenoyloxy]-4-(trimethylazaniumyl)butanoate

C29H47NO4 (473.3504902)


Clupanodonyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] Clupanodonyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).

   

(7Z,10Z,13Z,16Z,19Z)-Docosapentaenoylcarnitine

(7Z,10Z,13Z,16Z,19Z)-docosapentaenoylcarnitine

C29H47NO4 (473.3504902)


(7Z,10Z,13Z,16Z,19Z)-Docosapentaenoylcarnitine is an acylcarnitine. More specifically, it is an (7Z,19Z)-docosa-7,10,13,16,19-pentaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7Z,10Z,13Z,16Z,19Z)-Docosapentaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (7Z,10Z,13Z,16Z,19Z)-Docosapentaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(7E,10E,13E,16E,19E)-Docosapentaenoylcarnitine

3-(docosa-7,10,13,16,19-pentaenoyloxy)-4-(trimethylazaniumyl)butanoate

C29H47NO4 (473.3504902)


(7E,10E,13E,16E,19E)-Docosapentaenoylcarnitine is an acylcarnitine. More specifically, it is an (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7E,10E,13E,16E,19E)-Docosapentaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (7E,10E,13E,16E,19E)-Docosapentaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   
   

23-Acetoxy-25-episoladulcidine

23-Acetoxy-25-episoladulcidine

C29H47NO4 (473.3504902)


   

23-acetoxysoladulcidine

16-hydroxy-5,7,9,13-tetramethyl-5-oxaspiro[pentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosane-6,2-piperidine]-3-yl acetate

C29H47NO4 (473.3504902)


An organic heterohexacyclic compound that is soladulcidine carrying an acetoxy substituent at position 23

   

23R-Acetoxytomatidine

23R-Acetoxytomatidine

C29H47NO4 (473.3504902)


   

22,26-epimino-16beta,23-epoxy-23alpha-ethoxy-5alpha,25alphaH-cholest-22(N)-ene-3beta,20alpha-diol

22,26-epimino-16beta,23-epoxy-23alpha-ethoxy-5alpha,25alphaH-cholest-22(N)-ene-3beta,20alpha-diol

C29H47NO4 (473.3504902)


   
   
   
   

(Z)-2-tetracos-15-enamidoethanesulfonic acid

(Z)-2-tetracos-15-enamidoethanesulfonic acid

C26H51NO4S (473.3538606000001)


   

Adrenyl carnitine

Docosa-4,7,10,13,16-pentaenoyl carnitine

C29H47NO4 (473.3504902)


   

Clupanodonyl carnitine

Clupanodonyl carnitine

C29H47NO4 (473.3504902)


   

CAR 22:5

3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyloxy]-4-(trimethylammonio)butanoate;all-cis-7,10,13,16,19-docosapentaenoylcarnitine

C29H47NO4 (473.3504902)


   

NAT 24:1

N-(15Z-tetracosenoyl) taurine

C26H51NO4S (473.3538606000001)


   

(7E,10E,13E,16E,19E)-Docosapentaenoylcarnitine

(7E,10E,13E,16E,19E)-Docosapentaenoylcarnitine

C29H47NO4 (473.3504902)


   

(3R,19R)-19-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyicosanoate

(3R,19R)-19-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyicosanoate

C26H49O7- (473.3478104)


   

(3R)-20-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyicosanoate

(3R)-20-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyicosanoate

C26H49O7- (473.3478104)


   

(4E,7E,10E,13E,16E,19E)-docosahexaenoylcarnitine

(4E,7E,10E,13E,16E,19E)-docosahexaenoylcarnitine

C29H47NO4 (473.3504902)


An O-acylcarnitine in which the acyl group is specified as (4E,7E,10E,13E,16E,19E)-docosahexaenoyl.

   

Docosa-4,7,10,13,16-pentaenoyl carnitine

Docosa-4,7,10,13,16-pentaenoyl carnitine

C29H47NO4 (473.3504902)


   

O-[(7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl]carnitine

O-[(7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl]carnitine

C29H47NO4 (473.3504902)


An O-acylcarnitine having (7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl as the acyl substituent.

   
   

bhas#36(1-)

bhas#36(1-)

C26H49O7 (473.3478104)


Conjugate base of bhas#36

   

bhos#36(1-)

bhos#36(1-)

C26H49O7 (473.3478104)


Conjugate base of bhos#36

   

(4E,7E,10E,13E,16E)-docosapentaenoylcarnitine

(4E,7E,10E,13E,16E)-docosapentaenoylcarnitine

C29H47NO4 (473.3504902)


An O-acylcarnitine in which the acyl group is specified as (4E,7E,10E,13E,16E)-docosapentaenoyl.

   
   
   
   

(1r,3s,4r,7s,9s,12r,13s,15s,16s)-7-hydroxy-16-[(1r)-1-[(2r,3r,5s)-3-hydroxy-1,5-dimethylpiperidin-2-yl]ethyl]-4,17,17-trimethyl-18-oxapentacyclo[13.2.1.0¹,¹³.0³,¹².0⁴,⁹]octadecan-10-one

(1r,3s,4r,7s,9s,12r,13s,15s,16s)-7-hydroxy-16-[(1r)-1-[(2r,3r,5s)-3-hydroxy-1,5-dimethylpiperidin-2-yl]ethyl]-4,17,17-trimethyl-18-oxapentacyclo[13.2.1.0¹,¹³.0³,¹².0⁴,⁹]octadecan-10-one

C29H47NO4 (473.3504902)


   

2,11-dihydroxy-9a,11a-dimethyl-1-[1-(5-methylpiperidin-2-yl)ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl acetate

2,11-dihydroxy-9a,11a-dimethyl-1-[1-(5-methylpiperidin-2-yl)ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl acetate

C29H47NO4 (473.3504902)


   

(1r,2r,3ar,3br,7s,9ar,9bs,11s,11as)-2,11-dihydroxy-9a,11a-dimethyl-1-[(1s)-1-[(2r,5s)-5-methylpiperidin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl acetate

(1r,2r,3ar,3br,7s,9ar,9bs,11s,11as)-2,11-dihydroxy-9a,11a-dimethyl-1-[(1s)-1-[(2r,5s)-5-methylpiperidin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl acetate

C29H47NO4 (473.3504902)